Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement.
Choudry. Fizzah A FA; Yeo. Chia C; Mozid. Abdul A; Martin. John F JF; Mathur. Anthony A
Key Findings
- Plasma thymosin‑beta‑4 spikes 24 hours after intracardiac stem‑cell injection
- Higher thymosin‑beta‑4 levels linked to better NYHA symptom class
- Study involved only 13 treated patients and 14 controls, making results preliminary
Practical Outcomes
- The result is interesting but not directly usable: it suggests thymosin‑beta‑4 may be a marker of heart repair, yet there’s no dosage or supplement protocol to apply. More research is needed before biohackers could consider taking or dosing this peptide for heart health.
Summary
In a tiny study of people with chronic heart failure, injecting bone‑marrow stem cells into the heart caused a short‑term rise in a natural protein called thymosin‑beta‑4, and those who showed the biggest rise also felt less short‑of‑breath. The work is early and uses a surgical procedure, so it doesn’t give a clear way for everyday health‑hackers to use the peptide.
Abstract
Tβ4 is an integral factor in repair of myocardium in animal models. To investigate whether Tβ4 is important in human cardiac disease and has a role in mediating the beneficial cardiac effects of bone-marrow-derived stem cell (BMSC) therapy, we measured serial plasma Tβ4 levels in patients enrolled on the REGENERATE-IHD cell therapy trial. Plasma Tβ4 concentrations were measured in 13 patients who received BMSCs and 14 controls. There was a significant increase in plasma Tβ4 in the BMSC group 24 h after intracardiac injection. Increases in Tβ4 levels were associated with improvement in New York Heart Association symptom class. This exploratory study highlights the need for further study of Tβ4 in human cardiovascular disease.
Study Information
pubmed
2015
2015-05-29T00:00:00.000Z
10.2217/rme.15.9
5
22